Key Takeaway: Nurix is advancing NX-5948, a brain-penetrant BTK degrader, which has demonstrated clinical activity in treating B-cell malignancies, including CNS lymphoma. The company focuses on translating scientific insights into innovative therapies for cancer and autoimmune diseases. Their commitment to developing a multi-modal portfolio positions them well in the competitive biopharma landscape.
Price reaction · baseline $13.8 (2024-04-08 close) · hit pre-market · 4 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
+26.7%
day 1
+13.7%
day 3
+21.3%
Market Sentiment Analysis
POSITIVE FACTORS
NX-5948 shows clinical activity in B-cell malignancies.
The drug is a brain-penetrant BTK degrader.
Nurix is advancing its multi-modal portfolio.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-5948?
NX-5948 is a brain-penetrant BTK degrader developed by Nurix.
What types of cancer does NX-5948 target?
NX-5948 targets B-cell malignancies, including CNS lymphoma.
What is Nurix's focus in drug development?
Nurix focuses on translating scientific insights into breakthrough therapies.
What is a BTK degrader?
A BTK degrader is a type of drug that targets and degrades Bruton's tyrosine kinase.